Compass Therapeutics Inc Stock Price, News & Analysis

Compass Therapeutics (NASDAQ: CMPX) reported significant progress in Q1 2025, highlighted by tovecimig meeting its primary endpoint in the Phase 2/3 COMPANION-002 study for biliary tract cancer (BTC). The drug achieved a 17.1% overall response rate compared to 5.3% for paclitaxel alone. The company also advanced other pipeline candidates, including CTX-10726 (PD-1 x VEGF-A bispecific antibody) and CTX-8371.

Financial results showed a net loss of $16.6 million ($0.12 per share) compared to $10.8 million in Q1 2024. R&D expenses increased 37% to $13.1 million, while G&A expenses rose 51% to $4.9 million. The company maintains a strong financial position with $113 million in cash, providing runway into 2027.

Compass Therapeutics (NASDAQ: CMPX), a clinical-stage biopharmaceutical company focused on developing antibody-based cancer therapeutics, has announced its participation in two major investor events in May 2025. The company will present at The Citizens Life Sciences Conference in New York on May 8, 2025, at 1:30 PM ET, and at the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ on May 20, 2025, at 11:30 AM ET. Both presentations will be available via webcast and archived for 90 days on Compass' Events page.

Compass Therapeutics (NASDAQ: CMPX) presented promising preclinical data at the AACR Annual Meeting regarding the combination of CTX-471 and tovecimig in cancer treatment. The research demonstrated enhanced anti-tumor efficacy in checkpoint-refractory models.

The study showed that CTX-471 monotherapy was effective in multiple murine models resistant to immune checkpoint inhibitors. When combined with tovecimig, the treatment showed increased effectiveness through enhanced innate and adaptive anti-tumor immunity, improved tumor cell killing, and increased antigen presentation and interferon signaling.

The research utilized novel mouse tumor models engineered to mimic HLA loss in patients, including CT26B2m and MC38B2m knockout models. The combination therapy showed particular promise in cases where conventional checkpoint inhibitors, such as anti-PD-1 and anti-PD-L1 antibodies, have failed.

Compass Therapeutics (CMPX) has initiated dosing in a new Investigator Sponsored Trial (IST) evaluating tovecimig as a first-line treatment for biliary tract cancer (BTC). The trial, conducted at MD Anderson Cancer Center, will study tovecimig in combination with gemcitabine, cisplatin, and durvalumab in approximately 50 patients with unresectable or metastatic BTC.

The study includes a safety run-in phase with 12 patients, followed by an expansion phase with 38 additional patients. Primary objectives include assessing 6-month progression-free survival, safety, and determining maximum tolerated dose. The company recently announced that tovecimig met its primary endpoint in their ongoing Phase 2/3 second-line BTC study, with secondary endpoint results expected in Q4 2025.

Compass Therapeutics (Nasdaq: CMPX), a clinical-stage biopharmaceutical company focused on developing antibody-based cancer therapeutics, has announced its participation in the Stifel 2025 Virtual Targeted Oncology Forum.

The company's presentation is scheduled for Tuesday, April 8, 2025, at 3:00 PM EDT. Investors and interested parties can access the presentation through a webcast link, and a replay will be available on Compass' Events page for 90 days following the event.

Compass Therapeutics (NASDAQ: CMPX) announced significant results from its Phase 2/3 COMPANION-002 trial evaluating tovecimig in combination with paclitaxel for biliary tract cancer (BTC). The study met its primary endpoint, demonstrating a 17.1% overall response rate (ORR) for the combination therapy compared to 5.3% for paclitaxel alone (p=0.031).

The trial enrolled 168 patients with advanced BTC in the second-line setting, randomized 2:1 to receive tovecimig plus paclitaxel (n=111) or paclitaxel alone (n=57). Notable findings include one complete response in the combination arm and lower progressive disease rates (16.2% vs 42.1%). Secondary endpoints, including progression-free survival and overall survival, are expected to be reported in Q4 2025.

This development is particularly significant as approximately 23,000 BTC patients are diagnosed annually in the US, with 85% lacking approved second-line treatment options.

Compass Therapeutics (Nasdaq: CMPX) has announced a webcast scheduled for April 1, 2025, at 8:00 AM ET to present top-line clinical data from their ongoing Phase 2/3 COMPANION-002 trial. The study evaluates tovecimig, a DLL4 x VEGF-A bispecific antibody, in combination with paclitaxel for treating patients with advanced biliary tract cancer (BTC).

The virtual event will be accessible via webcast, with a replay available for 90 days on Compass' Events page.

Compass Therapeutics (NASDAQ: CMPX) reported its 2024 financial results and provided key pipeline updates. The company's lead candidate tovecimig is on track for Phase 2/3 top-line data readout in biliary tract cancer by Q1 2025. The company ended 2024 with $127 million in cash, providing runway into Q1 2027.

Financial highlights include a net loss of $49.4 million ($0.36 per share) compared to $42.5 million in 2023. R&D expenses increased 11% to $42.3 million, while G&A expenses rose 24% to $15.1 million.

Pipeline progress includes:

• Advancement of CTX-10726 (PD-1 x VEGF-A bispecific antibody) towards IND filing by end-2025
• Full enrollment of third dosing cohort for CTX-8371 Phase 1 study
• Planned initiation of two Phase 2 trials in mid-2025 for tovecimig and CTX-471
• 5% ORR achieved for tovecimig in colorectal cancer patients

Compass Therapeutics (Nasdaq: CMPX), a clinical-stage oncology-focused biopharmaceutical company, has announced its upcoming participation in the Guggenheim Securities SMID Cap Biotech Conference in New York City. The company, which specializes in developing proprietary antibody-based therapeutics, will deliver a corporate presentation on Thursday, February 6, 2025, from 9:00-9:25 AM EST.

The presentation will be accessible via webcast, and a replay will remain available for 90 days on Compass' Events page. This conference, scheduled for February 5-6, 2025, provides an opportunity for Compass to showcase its developments in treating multiple human diseases.